FindTrial
Sign In

Comparison of Incidence and Severity of conjunctival hyperemia associated with use of topical Bimatoprost 0.01% and latanoprost 0.005% in Glaucoma or Ocular Hypertensive patients - ND

Comparison of Incidence and Severity of conjunctival hyperemia associated with use of topical Bimatoprost 0.01% and latanoprost 0.005% in Glaucoma or Ocular Hypertensive patients - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2010-020213-82-IT
Enrollment
Unknown
Registered
2010-09-28
Start date
2010-05-27
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma or ocular hypertension MedDRA version: 9.1 Level: LLT Classification code 10018304 MedDRA version: 9.1 Level: LLT Classification code 10018304 MedDRA version: 9.1 Level: LLT Classification code 10018304 MedDRA version: 9.1 Level: PT Classification code 10018304

Interventions

Trade Name: lumigan 0.1 Pharmaceutical Form: Eye drops, solution INN or Proposed INN: Bimatoprost Concentration unit: % percent Concentration type: equal Concentration number: .01- Trade Name: XALATA

Sponsors

IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: glaucoma and ocular hypertension Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: other major ocular diseases

Design outcomes

Primary

MeasureTime frame
Main Objective: to compare conjuntival Hyperemia caused by two different treatments (lumigan 0.01% vs xalatan);Secondary Objective: to compare the efficacy in lowering ocular pressure of two different treatments( lumigan 0.01% vs xalatan);Primary end point(s): to compare ocular Hyperemia caused by two different treatments ( lumigan 0.01% or xalatan)—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026